Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

No head-to-head studies exist comparing BRAF inhibitor/MEK inhibitor (BRAFi/MEKi) combination treatments for BRAF-mutant melanoma. A side-by-side analysis of randomized phase III trials is presented that evaluated dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib. The basel...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Omid, Cowey, C. Lance, Offner, Michelle, Faries, Mark, Carvajal, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895913/
https://www.ncbi.nlm.nih.gov/pubmed/31653096
http://dx.doi.org/10.3390/cancers11111642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895913/
https://www.ncbi.nlm.nih.gov/pubmed/31653096
http://dx.doi.org/10.3390/cancers11111642

Ejemplares similares